Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Antibiotic-Free Feed Additive Shows Benefit in Cow Mastitis Trial
News Update

Share on Stocktwits


Avivagen's proprietary product yielded statistically significant results.

In a news release, Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced that its OxC-beta™ Livestock helped resolve subclinical mastitis in the cow subjects of a livestock dairy trial in New Zealand.

Mastitis, inflammation of the mammary gland, is a costly disease as cows infected with it must be treated with antibiotics, and this means that until their infection fully clears, their milk cannot be produced and sold commercially. U.S. dairy producers lose more than $2 billion in production each year due to mastitis.

Specifically, the study data showed that "100% more udder-quarters from cows fed OxBC (oxidized beta carotene) underwent spontaneous resolution of bacterial infection compared to quarters from cows fed the control feed containing no antibiotics," the release noted. Resolution in the OxC-beta group was 13.9% versus 6.9% in the control group.

Also, only one udder-quarter in the OxC-beta group progressed from subclinical to full clinical mastitis compared to six in the control group.

"We have assessed a number of compounds in terms of their ability to help clear subclinical mastitis, and this is the first time we have seen a positive effect," said Scott McDougall in the release. He is the managing director of Cognosco, the veterinary services and research group that conducted the trial. Starting on September 19, 2019, it spanned 42 days and took place at four commercial dairy farms on New Zealand's North Island.

These new results, taken with those of an earlier study in China, "demonstrate the effectiveness of supporting immune function to help improve chronic conditions that affect health and reduce productivity in dairy cows," according to the release. "These two trials are building out a consistent performance and use case for OxC-beta Livestock across geographies and in this significant dairy cow market."

Accordingly, Avivagen filed for patent protection for the use of OxC-beta Livestock in the treatment of dairy cows.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Want to read more about Nutraceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe